prohibits insurers from modifying an insured’s coverage of a prescription drug if drug had been previously preauthorized for coverage, the insured already received the drug, and a practitioner continues to prescribe the drug. If the Food and Drug Administration (FDA) has issued a statement calling into question the clinical safety of the drug or if the FDA has been notified of a manufacturing discontinuance or potential discontinuance of the drug, the measure does not prohibit modification of coverage. Any insurer that violates the provisions of this measure shall be subject to a civil penalty in an amount determined by the Insurance Commissioner.